Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472585 | 0.90 | RXRA (0.49) | RXRANR1H2NR1H3NR3C2IDH1 | |
| SCHEMBL3474579 | 0.85 | RXRA (0.47) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3471587 | 0.83 | RXRA (0.52) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3471500 | 0.83 | RXRA (0.51) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3473011 | 0.83 | RXRA (0.47) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3472501 | 0.82 | RXRA (0.52) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3472126 | 0.82 | RXRA (0.52) | RXRANR1H2NR1H3NR3C2FABP3 | |
| SCHEMBL3472663 | 0.82 | RXRA (0.51) | RXRANR1H2NR1H3NR3C2PTGS2 | |
| SCHEMBL3473666 | 0.81 | IDH1 (0.52) | RXRANR1H2NR1H3IDH1 | |
| SCHEMBL3472962 | 0.81 | RXRA (0.49) | RXRANR1H2NR1H3NR3C2FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.